Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABL103 + Pembrolizumab +/- Taxane in Advanced Solid Tumors
NCT07158918Phase 2Recruiting
- Sponsor
- ABL Bio
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ABL103 in solid tumor, sponsored by ABL Bio. Started Aug 2025; status: recruiting.
02
Drugs
ABL103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07158918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158918.